Drug Trial Radar · NCT06697899
TGRX-678 Phase I Oral Pharmacokinetic Study
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Nov 24, 2024
Primary completion
Jan 6, 2025
Study completion Feb 20, 2025
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- First posted
- Nov 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678
Conditions
- Chronic Myeloid Leukemia
Interventions
TGRX-678Drug
All participants are given TGRX-678 orally at 240 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma TmaxTime frame: During Treatment period (Day 1 to Day 43)
- Plasma TlagTime frame: During Treatment period (Day 1 to Day 43)
- Plasma CmaxTime frame: During Treatment period (Day 1 to Day 43)
- Plasma AUC(0-t)Time frame: During Treatment period (Day 1 to Day 43)
- Plasma AUC(0-inf)Time frame: During Treatment period (Day 1 to Day 43)
- AUC(%Extrap)Time frame: During Treatment period (Day 1 to Day 43)
- Half Life (T1/2)Time frame: During Treatment period (Day 1 to Day 43)
- Plasma volume of distribution (Vz/F)Time frame: During Treatment period (Day 1 to Day 43)
- Plasma clearance (CL/F)Time frame: During Treatment period (Day 1 to Day 43)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.